Renaissance Capital logo

Neon Therapeutics Priced, Nasdaq: NTGN

Developing a targeted immunotherapy platform for various cancers.

Industry: Health Care

First Day Return: -6.3%

We are a clinical-stage immuno-oncology company and a leader in the field of neoantigen-targeted therapies, dedicated to transforming the treatment of cancer by directing the immune system towards neoantigens. Genetic mutations, which are a hallmark of cancer, can result in specific immune targets called neoantigens. The presence of neoantigens in cancer cells and their absence in normal cells makes them compelling, untapped targets for cancer therapy. We believe our neoantigen-targeted therapies will offer a new level of patient and tumor specificity in the field of cancer immunotherapy. NEO-PV-01, our personal neoantigen vaccine, is custom-designed and manufactured based on the unique mutational fingerprint of each individual patient. An initial trial demonstrated the ability of a personal neoantigen vaccine to generate highly specific immune responses in six patients with stage III/IV melanoma, and NEO-PV-01 is being evaluated in an ongoing Phase 1b trial in combination with nivolumab in metastatic melanoma, non-small cell lung cancer and bladder cancer. NEO-PTC-01, our personal neoantigen T cell therapy, consists of multiple T cell populations that are generated to target each individual patient's unique set of neoantigens.

Neon Therapeutics (NTGN) Performance

Created with Highcharts 10.3.2Chart context menuNTGN vs. IPO Index (IPOUSA)Jul 2018Jul 20…Jan 2019Jul 2019Jan 2020Jul 2020Jan 2021Jul 2021Jan 2022Jul 2022Jan 2023Jul 2023Jan 2024Jul 2024Jan 2025Jul 20250%+ 100%+ 200%-100%View 5 days5dView 1 month1mView 3 months3mView year to dateYTDView 1 year1yView allAllRenaissance IPO IndexOur ETF tracks the IPO Index